HPV vaccine: 30% higher uptake than expected

Drug buyer Pharmac says there's been a 30% higher than predicted demand of the HPV vaccine, which protects against cervical, mouth, throat, penis and anal cancers. The human papillomavirus vaccine was funded for girls and young women nine years ago, with funding extended to boys and young men at the start of this year. There is currently a shortage of the HPV vaccine Gardasil 9. Kathryn Ryan speaks to Pharmac's Manager of Procurement and Contracts Greg Williams and Director of the Immunisation Advisory Centre at the University of Auckland Nikki Turner.